BR112022001847A2 - Uso de antagonistas multiméricos de e-selectina altamente potentes para tratamento da doença de células falciformes - Google Patents

Uso de antagonistas multiméricos de e-selectina altamente potentes para tratamento da doença de células falciformes

Info

Publication number
BR112022001847A2
BR112022001847A2 BR112022001847A BR112022001847A BR112022001847A2 BR 112022001847 A2 BR112022001847 A2 BR 112022001847A2 BR 112022001847 A BR112022001847 A BR 112022001847A BR 112022001847 A BR112022001847 A BR 112022001847A BR 112022001847 A2 BR112022001847 A2 BR 112022001847A2
Authority
BR
Brazil
Prior art keywords
sickle cell
cell disease
treatment
highly potent
selectin antagonists
Prior art date
Application number
BR112022001847A
Other languages
English (en)
Inventor
L Magnani John
E Fogler William
Original Assignee
Glycomimetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomimetics Inc filed Critical Glycomimetics Inc
Publication of BR112022001847A2 publication Critical patent/BR112022001847A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

uso de antagonistas multiméricos de e-selectina altamente potentes para tratamento da doença de células falciformes. são divulgados métodos para o tratamento de doença de células falciformes ou complicações associadas com as mesmas, incluindo, por exemplo, crise vaso-oclusiva, pelo uso de pelo menos um inibidor de e-selectina e composições compreendendo o mesmo.
BR112022001847A 2019-07-31 2020-07-30 Uso de antagonistas multiméricos de e-selectina altamente potentes para tratamento da doença de células falciformes BR112022001847A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962881297P 2019-07-31 2019-07-31
PCT/US2020/044177 WO2021021994A1 (en) 2019-07-31 2020-07-30 Use of highly potent multimeric e-selectin antagonists for treating sickle cell disease

Publications (1)

Publication Number Publication Date
BR112022001847A2 true BR112022001847A2 (pt) 2022-03-29

Family

ID=72087265

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001847A BR112022001847A2 (pt) 2019-07-31 2020-07-30 Uso de antagonistas multiméricos de e-selectina altamente potentes para tratamento da doença de células falciformes

Country Status (6)

Country Link
US (1) US20220257775A1 (pt)
EP (1) EP4003364A1 (pt)
BR (1) BR112022001847A2 (pt)
CA (1) CA3145263A1 (pt)
IL (1) IL290079A (pt)
WO (1) WO2021021994A1 (pt)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014014547B1 (pt) 2011-12-22 2022-09-27 Glycomimetics, Inc Composto, composição e métodos de uso
US11072625B2 (en) * 2016-10-07 2021-07-27 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
JP7304863B2 (ja) * 2017-12-29 2023-07-07 グリコミメティクス， インコーポレイテッド Ｅ－セレクチンおよびガレクチン－３のヘテロ二機能性阻害剤

Also Published As

Publication number Publication date
EP4003364A1 (en) 2022-06-01
CA3145263A1 (en) 2021-02-04
US20220257775A1 (en) 2022-08-18
IL290079A (en) 2022-03-01
WO2021021994A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
CO2019004137A2 (es) 1,2,4–triazolonas 2,4,5–trisustituidas
CL2018002920A1 (es) Nuevos derivados de pirazolopirimidina
DOP2019000117A (es) Nuevos derivados de quinolina
NI201900085A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
CO2020001244A2 (es) Derivados de quinolina para tratar infecciones con helmintos
BR112018008326A2 (pt) composições e métodos para o tratamento de câncer
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
BR112015032736A2 (pt) inibidores de bromodomínio cristalino
CO2019014484A2 (es) Nuevos derivados de azaquinolina
BRPI0821110B8 (pt) anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
CL2021001042A1 (es) Nuevos compuestos antihelmínticos
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
BRPI0518247A2 (pt) composiÇÕes compreendo inibidores de cinases jun n-terminais e uso
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
CO2020001242A2 (es) Dihidrooxadiazinonas
CO2020013876A2 (es) Nuevos derivados de quinolina
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CL2021001044A1 (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrización de heridas y la recuperación posoperatoria
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
BR112021025732A2 (pt) Inibidores macrocíclicos de mcl-1
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
UY31717A1 (es) (pirazolilcarbonil) imidazolidinonas sustituidas y su uso
BR112022001847A2 (pt) Uso de antagonistas multiméricos de e-selectina altamente potentes para tratamento da doença de células falciformes